Patents by Inventor Edmundo Brito-De La Fuente
Edmundo Brito-De La Fuente has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11975102Abstract: The invention relates to lyophilized products and reconstituted emulsions for parenteral application, which comprise all the 13 essential vitamins (A, D, E, K1, C, B1, B2, B3, B5, B6, B7, B9, and B12) in a single container, as well as to methods for preparing them.Type: GrantFiled: October 22, 2018Date of Patent: May 7, 2024Assignee: FRESENIUS KABI DEUTSCHLAND GMBHInventors: Getachew Assegehegn, Edmundo Brito De La Fuente, Crispulo Gallegos-Montes, Lida A. Quinchia Bustamante
-
Patent number: 11612578Abstract: The invention relates to PUFA, vitamin E, vitamin D and the protein bound amino acids glycine, arginine and tryptophan as active ingredients for use in therapy of patients with sarcopenia and/or frailty or pre-sarcopenic and/or pre-frail patients, wherein an effective amount of said active ingredients is administered in the form of a nutritional composition comprising a) a lipid component providing 40-50 EN % based on the total energy of the nutritional composition, wherein 12-16 EN % based on the total energy of the nutritional composition is provided by PUFA, b) 4.0-8.0 mg/100 mL alpha-TE vitamin E, c) 5.0-12.0 ?g/100 mL vitamin D, d) 2.5-4.5 g/100 mL glycine, e) 0.5-1.5 g/100 mL arginine, and f) at least 0.02 g/100 mL tryptophan.Type: GrantFiled: November 16, 2017Date of Patent: March 28, 2023Assignee: FRESENIUS KABI DEUTSCHLAND GMBHInventors: Edmundo Brito-De-La-Fuente, Ericka Pestana, Stephanie Reichart, Maria Fernanda Martinez-Bock, Sarah Ashley-Maguire, Jose Maria Mainou-Sierra
-
Patent number: 11406614Abstract: The present invention relates to the enhancement of the efficacy of anticancer agents by a composition comprising an aqueous phase, an oil phase, EPA and DHA for use in the treatment of solid tumors, wherein EPA and DHA are present in an amount of at least 65% based on the total weight of the oil phase wherein the composition comprises EPA and DHA in a weight ratio between 1:2 and 1:4, or wherein the composition comprises EPA and DHA in a weight ratio between 6:1 and 4:1 and wherein the treatment comprises administering the composition and administering at least one anticancer agent.Type: GrantFiled: October 5, 2017Date of Patent: August 9, 2022Assignee: Fresenius Kabi Deutschland GmbHInventors: Martin Westphal, Edmundo Brito De La Fuente, Crispulo Gallegos-Montes, Silke Baasner, Stefanie Honndorf, Lida Quinchia
-
Patent number: 11272728Abstract: Enteral tube feed for patients in an intensive care unit comprising a lipid component, a carbohydrate component and at least 30 EN % of a protein component based on the total energy content of the enteral tube feed, wherein the protein component comprises a peptide fraction consisting of di-, tri- and oligopeptides with a molecular weight of at most 1 kD, wherein the peptide fraction provides at least 10 EN % of the total energy content of the enteral composition and wherein the carbohydrate component predominantly consists of carbohydrates having a GI of ?35 such as isomaltulose for use in treatment of ICU patients.Type: GrantFiled: November 29, 2016Date of Patent: March 15, 2022Assignee: FRESENIUS KABI DEUTSCHLAND GMBHInventors: Edmundo Brito De La Fuente, Susanne Keim, Ericka Pestana
-
Publication number: 20210290526Abstract: The present disclosure relates to lipid emulsions for parenteral administration, comprising 10 to 30% of a lipid phase comprising soybean oil, medium-chain triglycerides (MCT), olive oil and fish oil and less than 25 mg, preferably less than 20 mg, campesterol, less than 30 mg, preferably less than 25 mg, stigmasterol and less than 120 mg, preferably less than 100 mg, betasitosterol per 100 g of the lipid phase. The present disclosure also relates to the lipid emulsions according to the present disclosure for providing parenteral nutrition, in particular to neonates, as well as to methods for manufacturing the lipid emulsions according to the present disclosure.Type: ApplicationFiled: July 1, 2019Publication date: September 23, 2021Inventors: Melanie DENKINGER, Ewald SCHLOTZER, Edmundo BRITO DE LA FUENTE, Lida A. Quinchia-Bustamante, Crispulo Gallegos-Montes
-
Patent number: 11058657Abstract: The invention relates to PUFA, vitamin E, vitamin D and the protein bound amino acids glycine, arginine and tryptophan as active ingredients for use in therapy of cancer patients, wherein an effective amount of said active ingredients is administered in the form of a nutritional composition comprising a) a lipid component providing 40-50 EN % based on the total energy of the nutritional composition, wherein 12-16 EN % based on the total energy of the nutritional composition is provided by PUFA, b) 4.0-8.0 mg/100 mL alpha-TE vitamin E, c) 5.0-12.0 ?g/100 mL vitamin D, d) 2.5-4.5 g/100 mL glycine, e) 0.5-1.5 g/100 mL arginine, and f) at least 0.02 g/100 mL tryptophan.Type: GrantFiled: November 16, 2017Date of Patent: July 13, 2021Assignee: Fresenius Kabi Deutschland GmbHInventors: Edmundo Brito-De-La Fuente, Ericka Pestana, Sarah Ashley-Maguire, Jose Maria Mainou-Sierra, Maria Fernanda Martinez-Bock, Stephanie Reichart
-
Publication number: 20200306215Abstract: The present invention relates to the enhancement of the efficacy of anticancer agents by a composition comprising an aqueous phase, an oil phase, EPA and DHA for use in the treatment of solid tumors, wherein EPA and DHA are present in an amount of at least 65% based on the total weight of the oil phase wherein the composition comprises EPA and DHA in a weight ratio between 1:2 and 1:4, or wherein the composition comprises EPA and DHA in a weight ratio between 6:1 and 4:1 and wherein the treatment comprises administering the composition and administering at least one anticancer agent.Type: ApplicationFiled: October 5, 2017Publication date: October 1, 2020Inventors: Martin Westphal, Edmundo BRITO DE LA FUENTE, Crispulo Gallegos-Montes, Silke Baasner, Stefanie HONNDORF, Lida Quinchia
-
Publication number: 20200297638Abstract: The invention relates to lyophilized products and reconstituted emulsions for parenteral application, which comprise all the 13 essential vitamins (A, D, E, K1, C, B1, B2, B3, B5, B6, B7, B9, and B12) in a single container, as well as to methods for preparing them.Type: ApplicationFiled: October 22, 2018Publication date: September 24, 2020Inventors: Getachew Assegehegn, Edmundo BRITO DE LA FUENTE, Crispulo GALLEGOS-MONTES, Lida A. Quinchia Bustamante
-
Publication number: 20200061013Abstract: The invention relates to PUFA, vitamin E, vitamin D and the protein bound amino acids glycine, arginine and tryptophan as active ingredients for use in therapy of patients with sarcopenia and/or frailty or pre-sarcopenic and/or pre-frail patients, wherein an effective amount of said active ingredients is administered in the form of a nutritional composition comprising a) a lipid component providing 40-50 EN % based on the total energy of the nutritional composition, wherein 12-16 EN % based on the total energy of the nutritional composition is provided by PUFA, b) 4.0-8.0 mg/100 mL alpha-TE vitamin E, c) 5.0-12.0 ?g/100 mL vitamin D, d) 2.5-4.5 g/100 mL glycine, e) 0.5-1.5 g/100 mL arginine, and f) at least 0.02 g/100 mL tryptophan.Type: ApplicationFiled: November 16, 2017Publication date: February 27, 2020Inventors: Edmundo BRITO-DE-LA-FUENTE, Ericka PESTANA, Stephanie REICHART, Maria Fernanda MARTINEZ-BOCK, Sarah ASHLEY, Jose Maria MAINOU-SIERRA
-
Publication number: 20200022941Abstract: The present invention relates to the treatment of liver diseases. In particular, it relates to a composition for use in treating and/or preventing a liver disease in a subject, wherein said composition comprises eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) wherein the ratio of EPA to DHA is at least 2:1.Type: ApplicationFiled: February 6, 2018Publication date: January 23, 2020Inventors: Martin Westphal, Silke Baasner, Stefanie HONNDORF, Edmundo BRITO DE LA FUENTE, Crispulo Gallegos-Montes, Lida Quinchia-Bustamante
-
Publication number: 20190374495Abstract: The invention relates to PUFA, vitamin E, vitamin D and the protein bound amino acids glycine, arginine and tryptophan as active ingredients for use in therapy of cancer patients, wherein an effective amount of said active ingredients is administered in the form of a nutritional composition comprising a) a lipid component providing 40-50 EN % based on the total energy of the nutritional composition, wherein 12-16 EN % based on the total energy of the nutritional composition is provided by PUFA, b) 4.0-8.0 mg/100 mL alpha-TE vitamin E, c) 5.0-12.0 ?g/100 mL vitamin D, d) 2.5-4.5 g/100 mL glycine, e) 0.5-1.5 g/100 mL arginine, and f) at least 0.02 g/100 mL tryptophan.Type: ApplicationFiled: November 16, 2017Publication date: December 12, 2019Inventors: Edmundo BRITO DE LA FUENTE, Ericka PESTANA, Sarah ASHLEY-MAGUIRE, José Maria MAINOU-SIERRA, Maria Fernanda MARTINEZ-BOCK, Stephanie REICHART
-
Patent number: 10342775Abstract: The present disclosure relates to emulsions for parenteral administration comprising 1000 to 5000, preferably 1500 to 3000 IU, vitamin A per ml, wherein the emulsions are free of polysorbates and polyoxyethylene/polyoxypropylene block copolymers. The present disclosure further relates to a method for manufacturing the compositions of the disclosure as well as to the use of the compositions of the disclosure.Type: GrantFiled: May 20, 2016Date of Patent: July 9, 2019Assignee: FRESENIUS KABI DEUTSCHLAND GMBHInventors: Edmundo Brito De La Fuente, Crispulo Gallegos-Montes, Lida A. Quinchia-Bustamente, Telli Hekmatara, Michael Betz
-
Patent number: 10206884Abstract: The present invention relates to microcapsules and to methods for them. The microcapsules comprise a polymeric coating that is at least partly crosslinked with a polymeric matrix comprising a polysaccharide. In the matrix, a lipid and an active agent or a prodrug or salt thereof are embedded, the lipid preferably having a melting point of at least 30° C. The microcapsules can be used as a medicament, dietary supplement or food additive, the microcapsules comprising a polymeric coating that is at least partly crosslinked with a polymeric matrix comprising a polysaccharide. As above, a lipid and an active agent or a prodrug or salt thereof are embedded in the matrix, with the lipid preferably having a melting point of at least 30° C. Methods for treating diarrhea or preventing colon cancer comprising administering such microcapsules are also disclosed.Type: GrantFiled: December 19, 2014Date of Patent: February 19, 2019Assignee: FRESENIUS KABI DEUTSCHLAND GMBHInventors: Michael Betz, Edmundo Brito De La Fuente, Crispulo Gallegos-Montes
-
Publication number: 20190037903Abstract: A nutritional composition comprises a protein component, a lipid component and a carbohydrate component, minerals, vitamins and water, wherein the protein component comprises at least two different protein sources; wherein the first protein source is hydrolysed collagen; the lipid component provides at least 30 EN % of the total energy of the composition and the first source of protein represents 35-95 wt % based on the total weight of the protein component. The nutritional composition provides a homogeneous emulsion of high energy density (e.g. at least 3 kcal/mL) and high protein density (e.g. at least 14 g/100 mL).Type: ApplicationFiled: February 3, 2017Publication date: February 7, 2019Applicant: Fresenius Kabi Deutschland GmbHInventors: Edmundo BRITO DE LA FUENTE, Susanne KEIM, Ericka Pestana, Jose Maria Mainou-Sierra, Maria Femanda MARTINEZ-BOCK, Eileen WALLENFELS, Susanne Wiegand
-
Publication number: 20180343912Abstract: Enteral tube feed for patients in an intensive care unit comprising a lipid component, a carbohydrate component and at least 30 EN % of a protein component based on the total energy content of the enteral tube feed, wherein the protein component comprises a peptide fraction consisting of di-, tri- and oligopeptides with a molecular weight of at most 1 kD, wherein the peptide fraction provides at least 10 EN % of the total energy content of the enteral composition and wherein the carbohydrate component predominantly consists of carbohydrates having a GI of ?35 such as isomaltulose for use in treatment of ICU patients.Type: ApplicationFiled: November 29, 2016Publication date: December 6, 2018Inventors: Edmundo BRITO DE LA FUENTE, Susanne KEIM, Ericka Pestana
-
Patent number: 10143674Abstract: Described herein are compositions that include an aqueous phase and 5 to 30%, by weight, of an oil phase, based on the total weight of the composition. The oil phase comprises the omega-3 fatty acid triglyceride eicosapentaenoic acid triglyceride, docosahexaenoic acid triglyceride, or mixtures thereof. The composition further comprises at least one amphoteric surfactant, at least one co-surfactant, and at least one co-solvent. The compositions comprise less than 0.03% by weight of sodium oleate, based on the total weight of the composition. Also described are methods for preparing such compositions as well as such compositions for use as a medicament, in particular for use in treating stroke, sepsis, Alzheimer's disease or cancer. Also featured are methods of treating these conditions by parenterally administering a composition to a patient in need and methods of providing parenteral nutrition to such patients by administering to them a composition as described herein.Type: GrantFiled: January 28, 2015Date of Patent: December 4, 2018Assignee: FRESENIUS KABI DEUTSCHLAND GMBHInventors: Edmundo Brito De La Fuente, Crispulo Gallegos-Montes, Lida A. Quinchia-Bustamente
-
Publication number: 20180185280Abstract: The present disclosure relates to emulsions for parenteral administration comprising propofol, wherein the free propofol concentration in the aqueous phase is below 0.1% of the total propofol content. The present disclosure further relates to a method for manufacturing the compositions of the disclosure as well as to the use of the compositions of the disclosure.Type: ApplicationFiled: June 30, 2016Publication date: July 5, 2018Inventors: Edmundo Brito De La Fuente, Crispulo Gallegos-Montes, Telli Hekmatara, Lida A. Quinchia-Busta-Mente
-
Publication number: 20180147174Abstract: The present disclosure relates to emulsions for parenteral administration comprising 1000 to 5000, preferably 1500 to 3000 IU, vitamin A per ml, wherein the emulsions are free of polysorbates and polyoxyethylen/polyoxypropylene block copolymers. The present disclosure further relates to a method for manufacturing the compositions of the disclosure as well as to the use of the compositions of the disclosure.Type: ApplicationFiled: May 20, 2016Publication date: May 31, 2018Inventors: Edmundo Brito De La Fuente, Crispulo Gallegos-Montes, Lida A. Quinchia-Bustamente, Telli Hekmatara, Michael Betz
-
Publication number: 20180000732Abstract: A method for manufacturing oil-in-water emulsions for parenteral administration as well as to the use of such emulsions in the treatment or prevention of malnutrition and/or a deficiency in essential fatty acids and/or EPA and DHA and or stroke, sepsis, Alzheimer's disease or cancer.Type: ApplicationFiled: March 31, 2016Publication date: January 4, 2018Inventors: Edmundo Brito De La Fuente, Getachew Assegehegn, Crispulo Gallegos-Montes, Telli Hekmatara, Lida A. Quinchia-Bustamente
-
Patent number: 9801846Abstract: Described herein are compositions for parenteral administration that include an aqueous phase and 5 to 30%, by weight, of an oil phase, based on the total weight of the composition. The oil phase comprises the omega-3 fatty acid ethylesters eicosapentaenoic acid ethylester, docosahexaenoic acid ethylester, and mixtures thereof. The composition further comprises at least one anionic surfactant and at least one amphoteric surfactant, and less than 0.05% by weight of oleic acid, based on the total weight of the composition. Also described is a method for preparing such a composition as well as such compositions for use as a medicament, in particular for use in treating stroke, sepsis, Alzheimer's disease or cancer. Also featured are methods of treating these conditions by parenterally administering a composition to a patient in need thereof and methods of providing parenteral nutrition to such patients by administering to them a composition as described herein.Type: GrantFiled: January 28, 2015Date of Patent: October 31, 2017Assignee: Fresenius Kabi Deutchland GmbHInventors: Edmundo Brito De La Fuente, Crispulo Gallegos-Montes, Lida A. Quinchia-Bustamente